Physician profile
Randall Scott
NPI 1619138658
$1,886.33
in general payments reported to CMS, 2019-2025
20 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.97 · 2020: $132 · 2021: $382 · 2022: $177 · 2023: $304 · 2024: $461 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $325.24 | 2020-2025 | Sublocade |
| Abbvie INC. | $322.91 | 2021-2025 | Vraylar |
| Amgen INC. | $280.03 | 2021-2025 | Repatha, Otezla, Repatha |
| Braeburn INC. | $162.24 | 2023-2025 | Brixadi |
| Novo Nordisk INC | $148.40 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $136.03 | 2020-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $115.51 | 2023-2025 | Airsupra, Breztri |
| Ferring Pharmaceuticals INC. | $77.69 | 2019-2023 | Euflexxa |
| Orexo US, INC. | $64.50 | 2023-2024 | Zubsolv |
| Gilead Sciences, INC. | $44.81 | 2019-2020 | |
| Exact Sciences Corporation | $30.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Insulet Corporation | $27.28 | 2025 | Omnipod |
| Corcept Therapeutics | $21.43 | 2023 | Korlym |
| Horizon Therapeutics Plc | $21.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.02 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19.67 | 2020 | |
| Impel Pharmaceuticals INC. | $19.63 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.05 | 2021 | |
| Aytu Biopharma, INC. | $14.72 | 2019 | |
| Cipher Pharmaceuticals US LLC | $14.68 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.